Stock listing

NASDAQ:ANGO AngioDynamics, Inc. Stock

Home listing (NASDAQ) of AngioDynamics, Inc.

Follow AngioDynamics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ANGO

$11.24 USD -0.34 (-2.9%)

Close on Oct 16, 2026

Since Jul 6, 2026 -13.4% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$11.06 – $11.73 USDOct 16, 2026
Volume
890,685 sharesOct 16, 2026
Market value
$472.7M USDAt the close on Oct 16, 2026 · price × 42.05M shares outstanding
AngioDynamics, Inc. logo
Ticker
NASDAQ:ANGO
Asset type
Stock
Sector
Health care
Industry
Medical devices & supplies
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Angiodynamics (NASDAQ:ANGO) Q1 2027 Earnings Call

    Thu, Oct 08, 2026 · 8:00 AM ET

    Watch Transcript

  • Angiodynamics (NASDAQ:ANGO) Q4 2026 Earnings Call

    Tue, Jul 14, 2026 · 8:00 AM ET

    Watch Transcript

  • Angiodynamics (NASDAQ:ANGO) Q3 2026 Earnings Call

    Thu, Apr 02, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

Oct 14, 2026

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

Oct 8, 2026

AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

Oct 8, 2026

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

Oct 2, 2026

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

Sep 28, 2026

Press space to expand and collapse this section AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

Jul 14, 2026

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

Jun 30, 2026

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

Jun 17, 2026

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

May 28, 2026

AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 27, 2026

All AngioDynamics, Inc. news

Decks

AngioDynamics, Inc. on 6ix

Sector
Health care
Industry
Medical devices & supplies
News releases
23 in the last 12 months · 139 in all · newest Oct 14, 2026 · oldest 2019
Calls
24 calls with a replay · 24 with a transcript · latest Oct 8, 2026
Decks
90 decks · latest Oct 8, 2026

Where AngioDynamics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ANGO · Home listing · This pageNASDAQUnited StatesUSD
gettex:UG2gettexGermanyEUR
LS Exchange:A0B9A5LS ExchangeGermanyEUR
BOATS:ANGOBOATSUnited StatesUSD
Lang & Schwarz:A0B9A5Lang & SchwarzGermanyEUR
Tradegate:UG2TradegateGermanyEUR
Dusseldorf:UG2DusseldorfGermanyEUR
Frankfurt:UG2FrankfurtGermanyEUR
Munich:UG2MunichGermanyEUR
Stuttgart:UG2StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about AngioDynamics, Inc.